Navigation Links
Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech
Date:6/28/2009

dification. By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Sangamo also has a Phase 1 clinical trial to evaluate safety and clinical effect of a ZFP Therapeutic for the treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its ZFP Technology, including Dow AgroSciences, Sigma-Aldrich Corporation Genentech and Pfizer. For more information about Sangamo and the ZFP Technology, visit www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs, strategic relationship with collaborators and achievement of research milestones, and research applications of Sangamo's ZFP technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, the ability of Sangamo and its collaborators to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. Sang
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
2. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
3. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
4. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
5. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
6. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
7. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
8. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
9. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
10. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
11. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... Research and Markets( ... "Future Horizons and Growth Strategies in the ... Country Forecasts" report to their offering. ... European Blood Banking Market 2015 is a new ... suppliers and potential market entrants identify and evaluate ...
(Date:7/1/2015)... , July 1, 2015 Rock Creek Pharmaceuticals, ... focused on chronic inflammatory disease and neurologic disorders, announced ... study with anatabine citrate, the Company,s lead compound. Results ... of anatabine citrate can significantly inhibit the activation of ... Company is developing this compound in a Phase 1 ...
(Date:7/1/2015)... , July 1, 2015  BioPharmX Corporation (NYSE MKT: ... underwritten public offering of 3,636,364 shares of its common ... per share. BioPharmX has granted the underwriters a 30-day ... common stock at the public offering price. ... an existing stockholder, has agreed to purchase 1,081,081 shares ...
Breaking Medicine Technology:European Blood Banking 2015: Future Horizons and Growth Strategies - Supplier Shares and Country Forecasts 2European Blood Banking 2015: Future Horizons and Growth Strategies - Supplier Shares and Country Forecasts 3Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 2Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 3Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 4BioPharmX Corporation Closes Underwritten Public Offering of Common Stock 2BioPharmX Corporation Closes Underwritten Public Offering of Common Stock 3
... Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ) today announced ... Against Rheumatism (EULAR) 2011 Annual Congress.  The conference will take ... and will feature the abstracts as two oral presentations and ... and the poster session will address the prevalence of gout ...
... BROOMFIELD, Colo., April 28, 2011 Biodesix announces the ... of the Addario Lung Cancer Medical Institute (ALCMI, pronounced ... Cancer) study is recruiting a minimum of 250 subjects ... in the United States. The study collects biospecimens and ...
Cached Medicine Technology:Savient Pharmaceuticals to Present Multiple Abstracts at The European League Against Rheumatism (EULAR) 2011 Annual Congress 2Biodesix Supports Unique Lung Cancer Research Initiative 2Biodesix Supports Unique Lung Cancer Research Initiative 3
(Date:7/2/2015)... ... July 02, 2015 , ... Patton State ... of State Hospitals. Prior to using Winscribe’s dictation and clinical documentation solutions, Patton ... to manage their organization’s dictation and transcription processes. , Over the ...
(Date:7/1/2015)... ... ... In the United States, summer has always been the season to travel ... Dubai, the summer temperatures are so hot, that July vacationers often leave their home ... ORA Dentistry Spa notes that a trip to the United States, and Los Angeles ...
(Date:7/1/2015)... ... , ... For decades, researchers in the genetics field have theorized that the ... changing after development in the womb. Now, researchers from the Icahn School of Medicine ... life – a process which helps to switch genes on and off. This histone ...
(Date:7/1/2015)... ... July 01, 2015 , ... A healthy eating ... chickens and eggs. Eating organic foods and products can help limit the exposure ... friendly than production chicken farming. Choosing home raised chickens and eggs that do ...
(Date:7/1/2015)... ... July 01, 2015 , ... OncLive® will ... of America (HCA), as it further expands its Strategic Alliance Partnership Program for ... this new partnership, OncLive’s editorial and marketing teams will collaborate with Sarah Cannon ...
Breaking Medicine News(10 mins):Health News:Patton State Hospital Saves Over 50% and Removes Document Backlogs with Winscribe Text 2Health News:Patton State Hospital Saves Over 50% and Removes Document Backlogs with Winscribe Text 3Health News:Patton State Hospital Saves Over 50% and Removes Document Backlogs with Winscribe Text 4Health News:Dr. Sam Saleh Invites Vacationing International Patients to Get a Same-Day Hollywood Smile During the July Travel Season 2Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 2Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 3Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 4Health News:Chicken Coop Condo Offer New Chicken Coop Designs 2Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 2Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 3
... , TUESDAY, Oct. 25 (HealthDay News) -- ... have a major effect on the rate at which ... The study included 144 experienced U.S. male pilots over ... Administration-approved flight simulator test three times over two years. ...
... as angiotensin-receptor blockers could reduce risk of mortality in ... (AS) by 30 per cent over an eight-year period, ... delegates at the Canadian Cardiovascular Congress. The condition is ... shifts how we think about AS by looking at ...
... MONDAY, Oct. 24 (HealthDay News) -- Teens who drink lots ... suggests. But the study authors concede that sodas are ... there,s a chance that the sugar and caffeine from carbonated ... not a cause-and-effect. Soda consumption, for example, may be a ...
... MONDAY, Oct. 24 (HealthDay News) -- Cancer-causing strains of ... for heart disease, even if she doesn,t have any ... suggests. It,s the first investigation of a possible ... of the most common sexually transmitted pathogens in the ...
... A model used to estimate breast cancer survival rates found ... will avoid a breast cancer death because of screening mammography ... published Online First by Archives of Internal Medicine , ... likely to know a cancer survivor than ever before," the ...
... D.C. Pat Furlong founded Parent Project Muscular Dystrophy (PPMD) ... affected by muscular dystrophy with both resources and hope. Now, ... end the disease. She has spearheaded a partnership between PPMD ... open-access publication, PLoS Currents: Muscular Dystrophy, this month. The story ...
Cached Medicine News:Health News:Aging Brain's Decline May Hinge on a Gene 2Health News:Double duty for blood pressure drugs: how they could revolutionize how we treat valve disease 2Health News:Double duty for blood pressure drugs: how they could revolutionize how we treat valve disease 3Health News:Soft Drinks Linked to Violent Tendencies in Teens: Study 2Health News:Soft Drinks Linked to Violent Tendencies in Teens: Study 3Health News:Could HPV Raise Women's Risk for Heart Disease? 2Health News:Could HPV Raise Women's Risk for Heart Disease? 3Health News:Probability model estimates proportion of women who survive breast cancer detected through screening 2Health News:Probability model estimates proportion of women who survive breast cancer detected through screening 3Health News:Probability model estimates proportion of women who survive breast cancer detected through screening 4Health News:Patient advocacy groups turn to open-access publishing to advance research quest 2
The TBS-380 Fluorometer is an economical, sensitive fluorometer designed for quick, easy, and accurate fluorescent measurements....
... capsular bag in cases of damaged or ... for scleral fixation with suture. Robert J. ... recognized from his early experience using the ... need for greater stability when confronted with ...
Liquid, ready-to-use, bar-coded Olympus reagents are convenient, economical easy-to-use and reliable. This is one of 122 tests standardized for use on the Olympus AU400e, AU640e, AU2700, and AU5400 C...
Liquid, ready-to-use, bar-coded Olympus reagents are convenient, economical easy-to-use and reliable. This is one of 122 tests standardized for use on the Olympus AU400e, AU640e, AU2700, and AU5400 C...
Medicine Products: